Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

170105

registered interest
date	12/12/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will make an assessment of the potential merits of allowing two Patient Access Schemes for one treatment; and if he will make a statement.
tabling member constituency	Southend West
tabling member printed	Mr David Amess
uin	218554
answer	answer is ministerial correction date of answer 17/12/2014 answer text <p>Whilst we recognise there are benefits to be derived from Patient Access Schemes (PAS), both the 2009 and 2014 Pharmaceutical Price Regulation Schemes (PPRS), negotiated with the United Kingdom pharmaceutical industry, set out that PAS should be the exception rather than the rule. It is important that PAS are operationally manageable for the National Health Service, and any burden for the NHS should be proportionate to the benefits of the PAS for the NHS and patients.</p><p> </p><p> </p><p> </p><p>The 2009 and 2014 schemes set out the Department’s and the Association of the British Pharmaceutical Industry’s commitment to ensure that the cumulative burden on all parties involved in the operation of PAS is manageable. The PPRS recognises that it is reasonable for the Department to take this issue into account when considering the viability of individual PAS proposals.</p><p> </p><p> </p><p> </p><p>The 2014 PPRS states that the Department is unlikely to agree more than one PAS for a single product because of the complexity this would introduce for the NHS.</p><p> </p><p><strong> </strong></p><p> </p><p> </p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 218458 question first answered 17/12/2014 17:16:52 answering member 4020 label Biography information for George Freeman
tabling member	44 label Biography information for Sir David Amess

169978

registered interest
date	11/12/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, whether his Department has any plans to allow two Patient Access Schemes for one treatment; and if he will make a statement.
tabling member constituency	Southend West
tabling member printed	Mr David Amess
uin	218458
answer	answer is ministerial correction date of answer 17/12/2014 answer text <p>Whilst we recognise there are benefits to be derived from Patient Access Schemes (PAS), both the 2009 and 2014 Pharmaceutical Price Regulation Schemes (PPRS), negotiated with the United Kingdom pharmaceutical industry, set out that PAS should be the exception rather than the rule. It is important that PAS are operationally manageable for the National Health Service, and any burden for the NHS should be proportionate to the benefits of the PAS for the NHS and patients.</p><p> </p><p> </p><p> </p><p>The 2009 and 2014 schemes set out the Department’s and the Association of the British Pharmaceutical Industry’s commitment to ensure that the cumulative burden on all parties involved in the operation of PAS is manageable. The PPRS recognises that it is reasonable for the Department to take this issue into account when considering the viability of individual PAS proposals.</p><p> </p><p> </p><p> </p><p>The 2014 PPRS states that the Department is unlikely to agree more than one PAS for a single product because of the complexity this would introduce for the NHS.</p><p> </p><p><strong> </strong></p><p> </p><p> </p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 218554 question first answered 17/12/2014 17:16:52 answering member 4020 label Biography information for George Freeman
tabling member	44 label Biography information for Sir David Amess

169841

registered interest
date	11/12/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Bladder Cancer: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment his Department has made of the effectiveness of the Anti-PD-L1 drug in treating bladder cancer.
tabling member constituency	Montgomeryshire
tabling member printed	Glyn Davies
uin	218285
answer	answer is ministerial correction date of answer 17/12/2014 answer text <p>Two Anti-PD monoclonal antibody products are being evaluated in clinical trials for various cancers, including bladder cancer.</p><p> </p><p> </p><p> </p><p>MPDL3280A, an anti-PD-L1 antibody made by Roche/Genentech, is undergoing a phase I trial (<a href="http://clinicaltrials.gov/ct2/show/NCT01375842" target="_blank">NCT01375842</a>) in patients with locally advanced or metastatic solid tumours. The estimated study completion date is November 2016. The product is also being tested in a phase II trial in in patients with locally advanced or metastatic urothelial bladder cancer (<a href="http://clinicaltrials.gov/ct2/show/NCT02108652" target="_blank">NCT02108652</a>). The estimated completion date for this Phase II trial is January 2016.</p><p> </p><p> </p><p> </p><p>The second anti-PD antibody is Nivolumab produced by Bristol-Myers Squibb. Nivolumab on its own, or in combination with another monoclonal antibody ipilimumab (Yervoy®), is in a phase I/II trial in several cancers, including bladder cancer (<a href="http://clinicaltrials.gov/show/NCT01928394" target="_blank">NCT01928394</a>). This trial is expected to be completed by March 2017.</p><p> </p><p> </p><p> </p><p>No assessment of the data from any of these trials has been made to date.</p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 17/12/2014 17:36:02 answering member 4020 label Biography information for George Freeman
tabling member	4041 label Biography information for Glyn Davies

169769

registered interest
date	11/12/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Autism
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many local authorities have an autism strategy.
tabling member constituency	Plymouth, Sutton and Devonport
tabling member printed	Oliver Colvile
uin	218270
answer	answer is ministerial correction date of answer 17/12/2014 answer text <p>This information is not recorded centrally. Local joint commissioning plans for services for adults with autism should be developed and updated based on effective joint strategic needs assessment. The second national Public Health England self-assessment exercise reported on progress being made by the end of September 2013 across all 152 local authority areas in England.</p><p> </p><p><br> Details can be found at:</p><p> </p><p> </p><p> </p><p><a href="http://www.ihal.org.uk/projects/autism2013" target="_blank">www.ihal.org.uk/projects/autism2013</a></p><p> </p><p> </p><p> </p><p>The exercise is a key means of identifying progress in implementing the strategy as a whole and for demonstrating local accountability. The most recent exercise started on 12 December 2014 for completion by 9 March 2015.</p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb question first answered 17/12/2014 17:42:56 answering member 1439 label Biography information for Norman Lamb
tabling member	4022 label Biography information for Oliver Colvile

170107

registered interest
date	12/12/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Maternity Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, on how many days maternity units at each (a) NHS Trust and (b) NHS Foundation were put on divert in the last 12 months.
tabling member constituency	City of Durham
tabling member printed	Roberta Blackman-Woods
uin	218539
answer	answer is ministerial correction date of answer 17/12/2014 answer text <p>This information is not collected centrally.</p><p> </p> answering member constituency Central Suffolk and North Ipswich answering member printed Dr Daniel Poulter grouped question UIN 218459 218460 question first answered 17/12/2014 17:40:06 answering member 3932 label Biography information for Dr Dan Poulter
tabling member	1501 label Biography information for Dr Roberta Blackman-Woods

169980

registered interest
date	11/12/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Maternity Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, for how many days maternity units at each (a) NHS trust and (b) NHS foundation trust were put on divert in the last 12 months.
tabling member constituency	City of Durham
tabling member printed	Roberta Blackman-Woods
uin	218460
answer	answer is ministerial correction date of answer 17/12/2014 answer text <p>This information is not collected centrally.</p><p> </p> answering member constituency Central Suffolk and North Ipswich answering member printed Dr Daniel Poulter grouped question UIN 218459 218539 question first answered 17/12/2014 17:40:05 answering member 3932 label Biography information for Dr Dan Poulter
tabling member	1501 label Biography information for Dr Roberta Blackman-Woods

169979

registered interest
date	11/12/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Maternity Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, on how many occasions maternity units at each (a) NHS trust and (b) NHS foundation trust were put on divert in the last 12 months.
tabling member constituency	City of Durham
tabling member printed	Roberta Blackman-Woods
uin	218459
answer	answer is ministerial correction date of answer 17/12/2014 answer text <p>This information is not collected centrally.</p><p> </p> answering member constituency Central Suffolk and North Ipswich answering member printed Dr Daniel Poulter grouped question UIN 218460 218539 question first answered 17/12/2014 17:40:05 answering member 3932 label Biography information for Dr Dan Poulter
tabling member	1501 label Biography information for Dr Roberta Blackman-Woods

169512

registered interest
date	10/12/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	General Practitioners
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, pursuant to the Answer of 8 December 2014 to Question 216134, if he will bring forward proposals to replace the National Education Programme on Health at Work.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	218003
answer	answer is ministerial correction date of answer 17/12/2014 answer text <p>There are no plans to replace the National Education Programme on Health at Work. The Fit for Work service will deliver both a supportive occupational health assessment and general health and work advice to general practitioners as well as employees and employers.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 17/12/2014 16:09:10 answering member 3918 label Biography information for Jane Ellison
tabling member	4036 label Biography information for Luciana Berger

170099

registered interest
date	12/12/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Health: Screening
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many GP-requested (a) chest x-ray, (b) non-obstetric ultrasound, (c) flexi-sigmoidoscopies, (d) colonoscopies and (e) brain MRIs took place in each of the last five years.
tabling member constituency	Leicester West
tabling member printed	Liz Kendall
uin	218536
answer	answer is ministerial correction date of answer 17/12/2014 answer text <p>The information requested is not available in the format requested.</p><p> </p><p> </p><p> </p><p>A breakdown of the number of diagnostic tests requested by general practitioners (GPs) is not collected separately. Information is collected on the number of diagnostic tests requested by all referrers, including GPs, and is shown in the table below.</p><p> </p><p> </p><p> </p><p>Number of non-obstetric ultrasounds, flexible sigmoidoscopy, colonoscopy and MRI tests, 2009-10 to 2013-14</p><p> </p><p> </p><p> </p><table><tbody><tr><td><p>Year</p></td><td><p>Number of Non-obstetric ultrasounds tests</p></td><td><p>Number of Flexible sigmoidoscopy</p><p>tests</p></td><td><p>Number of</p><p>Colonoscopy</p><p>tests</p></td><td><p>Number of MRI</p><p>tests</p></td></tr><tr><td><p>2009-10</p></td><td><p>5,073,625</p></td><td><p>197,342</p></td><td><p>315,657</p></td><td><p>1,895,842</p></td></tr><tr><td><p>2010-11</p></td><td><p>5,353,578</p></td><td><p>200,462</p></td><td><p>324,429</p></td><td><p>2,035,440</p></td></tr><tr><td><p>2011-12</p></td><td><p>5,592,035</p></td><td><p>217,767</p></td><td><p>360,443</p></td><td><p>2,192,511</p></td></tr><tr><td><p>2012-13</p></td><td><p>5,918,780</p></td><td><p>232,674</p></td><td><p>399,637</p></td><td><p>2,407,441</p></td></tr><tr><td><p>2013-14</p></td><td><p>6,314,999</p></td><td><p>228,756</p></td><td><p>401,278</p></td><td><p>2,667,286</p></td></tr></tbody></table><p> </p><p><em> </em></p><p> </p><p><em>Source: </em>Monthly diagnostic waiting times and activity, NHS England</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 17/12/2014 16:59:50 answering member 3918 label Biography information for Jane Ellison
tabling member	4026 label Biography information for Liz Kendall

169527

registered interest
date	10/12/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Tobacco: Packaging
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what detailed opinions have been submitted by organisations and corporate entities in response to the notification to the UK by the EU on proposals for standardised packaging of tobacco.
tabling member constituency	Shipley
tabling member printed	Philip Davies
uin	218147
answer	answer is ministerial correction date of answer 17/12/2014 answer text <p>The draft regulations for standardised packaging of tobacco were notified to the European Commission under the Technical Standards Directive (Directive 98/34/EC) on 29 August. This procedure allows other member states and the European Commission to examine the draft regulations and provide comments or detailed opinions.</p><p> </p><p> </p><p> </p><p> </p><p> </p><p>The notification and information about which member states responded can be found at:</p><p> </p><p> </p><p> </p><p><a href="http://ec.europa.eu/enterprise/tris/en/search/?trisaction=search.detail&amp;year=2014&amp;num=427" target="_blank">http://ec.europa.eu/enterprise/tris/en/search/?trisaction=search.detail&amp;year=2014&amp;num=427</a></p><p> </p><p> </p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 17/12/2014 16:10:21 answering member 3918 label Biography information for Jane Ellison
tabling member	1565 label Biography information for Sir Philip Davies